U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1001 - 1010 of 13259 results

Status:
Investigational
Source:
INN:belaperidone
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Belaperidone (LU111995) is a recently identified antipsychotic agent with high 5-hydroxytryptamine2 and dopamine D4 receptor affinities as well as D4 versus D2 receptor selectivity. The drug did not produce catalepsy. LU111995 prolongs the Q-T interval to a limited degree and is not arrhythmogenic over the physiological range of cycle lengths. Belaperidone had been in phase II clinical trials for the treatment of schizophrenia. However, the study about this drug candidate was discontinued.
Status:
Investigational
Source:
INN:batanopride
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Batanopride, previously known as BMY-25801, a 5-hydroxytryptamine 3 receptor antagonist, was studied against emesis for cancer patients that were treated by chemotherapy procedure. Batanopride had the dose-limiting side effects including hypotension and long QT syndrome that is why any further experiments for its medical application were discontinued.
Status:
Investigational
Source:
INN:lexacalcitol
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Lexacalcitol (KH1060) is over 100 times more active than 1alpha,25-dihydroxyvitamin D3 and is of potential interest in the treatment of psoriasis and other diseases characterized by accelerated cell growth and T lymphocyte activation, which was studied in the clinical trial. KH1060 also prevents type I diabetes in the preclinical investigation without significant effects on calcium or bone metabolism. In addition also was shown that neuroblastoma (NB) cell lines were more susceptible to growth inhibition by KH1060, suggesting its possible use in NB to potentiate the action of retinoids, which are in clinical use for this disease. The underlying biochemical reasons for the increased biological activity of KH1060 are unknown, but it can include 1) metabolic considerations in addition to explanations based upon 2) enhanced stability of KH1060-liganded transcriptional complexes.
Status:
Investigational
Source:
INN:lobuprofen [INN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Lobuprofen is an ester type analgesic, in which the acid moiety (ibuprofen) has peripheral analgesic activity and the alcohol moiety (mCPPol) has central analgesic activity.
Status:
Investigational
Source:
INN:dalbraminol [INN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Dalbraminol is a beta-adrenergic blocker, developed by Boehringer Mannheim.
Status:
Investigational
Source:
INN:ecopladib
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Ecopladib) is a sub-micromolar inhibitor of cytosolic phospholipase A2α (cPLA2α, type IVA phospholipase). Inhibitors of cPLA2alpha are predicted to be efficacious in treating asthma as well as the signs and symptoms of osteoarthritis, rheumatoid arthritis, and pain. It displayed oral efficacy in the rat carrageenan air pouch and rat carrageenan-induced paw edema models.
Status:
Investigational
Source:
INN:meglitinide
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)


Meglitinide (HB 699) is an antidiabetic compound. Meglitinide is a short-acting insulin secretagogue that targets one of the main defects that characterizes type 2 diabetes: the progressive loss of early phase prandial insulin secretion. It acts in a glucose-dependent manner to close adenosine triphosphate (ATP)-dependent potassium channels on the β-cell membrane, depolarize the β-cell, resulting in the opening of calcium channels, increased calcium influx and insulin secretion.
Status:
Investigational
Source:
INN:triclofylline
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Triclofylline is a N-methylated xanthine derivative. It was developed as an anti-asthmatic drug.
Status:
Investigational
Source:
INN:clentiazem
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Clentiazem is a chloride derivative of diltiazem, originated in Tanabe Seiyaku. It works as a blocker of calcium channels. The drug was investigated in the clinical trials for the treatment of stable angina, and essential hypertension. Despite the positive results of clinical trials, no development of the drug was reported.
Status:
Investigational
Source:
INN:eticyclidine [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Eticyclidine (N-ethyl-1-phenylcyclohexylamine) is a phencyclidine derivative exerting nearly the same pharmacological profile as the parent compound. In rodents, it induces stereotypy, ataxia, interoceptive effect and hypothermia.

Showing 1001 - 1010 of 13259 results